AB598
Phase 1Small molecule
Arcus BiosciencesAB598 is one of 16 small molecule programs targeting Advanced Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Advanced Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 1
Eloxatin
TevaPhase 1
Tukysa
PfizerPhase 1
Kisqali
NovartisPhase 1
Taxotere
AAvyxa
Phase 1
Adrucil
EElorac, Inc.
Phase 1
Psilocybin
COMPASS PathwaysPhase 2
Faslodex
FFresenius Kabi Oncology Ltd.
Phase 1
Herceptin
OOrganon and Co
Phase 1
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AB598. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company